1. Home
  2. FCNCP vs SCLXW Comparison

FCNCP vs SCLXW Comparison

Compare FCNCP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Citizens BancShares Inc.

FCNCP

First Citizens BancShares Inc.

HOLD

Current Price

$20.35

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.14

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FCNCP
SCLXW
Founded
N/A
N/A
Country
United States
United States
Employees
18141
34
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FCNCP
SCLXW
Price
$20.35
$0.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.8K
4.6K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
$19.97
$0.04
52 Week High
$22.86
$0.64

Technical Indicators

Market Signals
Indicator
FCNCP
SCLXW
Relative Strength Index (RSI) 32.46 45.65
Support Level $20.03 $0.11
Resistance Level $20.68 $0.18
Average True Range (ATR) 0.24 0.02
MACD -0.08 -0.00
Stochastic Oscillator 9.18 22.22

Price Performance

Historical Comparison
FCNCP
SCLXW

About FCNCP First Citizens BancShares Inc.

First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: